somatostatine-eumedica 250 µg inj. sol. (pwdr. + solv.) i.v. amp. vial
eumedica pharmaceuticals gmbh - somatostatin acetate hydrate - eq. somatostatin 250 µg - powder and solvent for solution for injection - 250 µg - somatostatin acetate hydrate - somatostatin
somatostatine-eumedica 3 mg inf. sol. (pwdr. + solv.) i.v. amp.
eumedica pharmaceuticals gmbh - somatostatin acetate hydrate - eq. somatostatin 3 mg - powder and solvent for solution for infusion - 3 mg - somatostatin acetate hydrate - somatostatin
somatostatine-eumedica 6 mg inj./inf. sol. (pwdr. + solv.) i.v. amp.
eumedica pharmaceuticals gmbh - somatostatin acetate hydrate - eq. somatostatin 6 mg - powder and solvent for solution for injection/infusion - 6 mg - somatostatin acetate hydrate - somatostatin
diclofenac potassium- diclofenac potassium tablets tablet, film coated
umedica laboratories private limited - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation). diclofenac potassium tablets are indicated: - for treatment of primary dysmenorrhea - for relief of mild to moderate pain - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac potassium tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions). - history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings; anaphylactic reactions, exacerbation of asthma related to aspirin sensitivity). - in the setting of coronary artery bypass graft (cabg) surgery (see warnings; cardiovascular thrombotic events).
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 0.25 mg iv 0.25mg/vial injection
modern pharmaceutical company belgium - 1 powder vial + 1 solvent ampoule (1ml) - injection - 0.25mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 0.25 mg iv 0.25mg/vial injection
modern pharmaceutical company belgium - 1 powder vial + 1 solvent ampoule (1ml) - injection - 0.25mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas
somatostatin-eumedica 3 mg iv 3mg/vial injection
modern pharmaceutical company belgium - 1 powder ampoule + 1 solvent ampoule (1ml) - injection - 3mg/vial - malignant disease,immunosuppresion-sex hormones , antagonists in malignant diseas